SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic

<b>Background and Aims</b>: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise in metabolic dysfunction-associated steatotic liver disease (MASLD). This large real-world study aimed to evaluate the effects of SGLT2 inhibitors on MASLD patients’ clinical outcomes and liv...

Full description

Bibliographic Details

Published in:	Pharmaceuticals
Main Authors:	Mohamad Suki, Ashraf Imam, Johnny Amer, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon, Yousra Sharif, Joseph Sackran, Revital Alon, Nachum Lourie, Anat Hershko Klement, Safa Shibli, Tamer Safadi, Itamar Raz, Abed Khalaileh, Rifaat Safadi
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Subjects:	SGLT2 inhibitors NAFLD MASLD liver outcomes cirrhosis mortality
Online Access:	https://www.mdpi.com/1424-8247/18/8/1118